The Use of Hydroxyurea in the Treatment of COVID-19

1Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782–793. doi:10.1001/jama.2020.12839Wiersinga WJ Rhodes A Cheng AC et al Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review JAMA 2020 324 8 782–793 10.1001/jama.2020.12839Open DOISearch in Google Scholar

2National Institutes of Health. Covid-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/whatsnew/National Institutes of Health Covid-19 Treatment Guidelines https://www.covid19treatmentguidelines.nih.gov/whatsnew/Search in Google Scholar

3Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. European Respiratory Journal. 2020; 55(5): 2001009. https://doi.org/10.1183/13993003.01009-2020Halpin DMG Singh D Hadfield RM Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective European Respiratory Journal 2020 55 5 2001009 doi.org/10.1183/13993003.01009-2020Open DOISearch in Google Scholar

4Tobin MJ. Basing respiratory management of COVID-19 on physiological principles. Am J Respir Crit Care Med. 2020;201(11):1319-1320. doi:10.1164/rccm.202004-1076EDTobin MJ Basing respiratory management of COVID-19 on physiological principles Am J Respir Crit Care Med 2020201 11 1319–1320 10.1164/rccm.202004-1076EDOpen DOISearch in Google Scholar

5Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Review. 2017; 4: CD002202. doi: 10.1002/14651858.CD002202.pun2.Nevitt SJ Jones AP Howard J Hydroxyurea (hydroxycarbamide) for sickle cell disease Cochrane Database of Systematic Review 2017 4 CD002202 10.1002/14651858.CD002202.pun2Open DOISearch in Google Scholar

6Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study.   Lancet Infectious Disease. 2020;20(4):425434. doi:10.1016/S1473-3099(20)30086-4Shi H Han X Jiang N et al Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study   Lancet Infectious Disease 202020 4 425434 10.1016/S1473-3099(20)30086-4Open DOISearch in Google Scholar

7Dhont S, Derom E, Van Braeckel E, et al. The pathophysiology of ‘happy’ hypoxemia in COVID-19. Respiratory Research. 2020; 21( 198). https://doi.org/10.1186/s12931-020-01462-5Dhont S Derom E Van Braeckel E et al The pathophysiology of ‘happy’ hypoxemia in COVID-19 Respiratory Research 2020 21 198 https://doi.org/10.1186/s12931-020-01462-510.1186/s12931-020-01462-5738571732723327Search in Google Scholar

8Khandros E, Huang P, Peslak SA, et al. Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts. Blood. 2020;135(22):1957-1968. doi:10.1182/blood.2020005058Khandros E Huang P Peslak SA et al Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts Blood 2020135 22 1957–1968 10.1182/blood.2020005058725635832268371Open DOISearch in Google Scholar

9Panepinto JA, Brandow AM, Singh A. Secure-SCD Registry. Medical College of Wisconsin. (October 2020) https://covidsicklecell.org/Panepinto JA Brandow AM Singh A Secure-SCD Registry Medical College of Wisconsin October 2020 https://covidsicklecell.org/Search in Google Scholar

10Ramachandran P, Perisetti A, Kathirvelu B, et al. Low morbidity and mortality with COVID-19 in sickle cell disease: A single center experience. eJHaem. 2020;1–7. https://doi.org/10.1002/jha2.87Ramachandran P Perisetti A Kathirvelu B et al Low morbidity and mortality with COVID-19 in sickle cell disease: A single center experience eJHaem 20201–7 https://doi.org/10.1002/jha2.8710.1002/jha2.87Search in Google Scholar